We're saying basically we think all biosimilars should be interchangeable. And then states have their own rules on whether or not patients need to be consented or not for substitution. So We're planting a flag saying we want interchangeability, we promote it, we encourage it. And look, I would love it if Congress solidified this in law, but we're not going to wait for them. Thank you. Hi, Paige Cunningham, Washington Post. (29:45–29:52)
CLAIM
Asserts that interchangeability of biosimilars is promoted and encouraged.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.